Regulus Therapeutics Inc. (NASDAQ:RGLS) was down 3.7% during trading on Wednesday . The company traded as low as $3.35 and last traded at $3.36, with a volume of 401,464 shares changing hands. The stock had previously closed at $3.49.

A number of equities research analysts have commented on RGLS shares. FBR & Co reissued an “outperform” rating and issued a $9.00 target price (down previously from $30.00) on shares of Regulus Therapeutics in a report on Tuesday, June 28th. Chardan Capital started coverage on Regulus Therapeutics in a report on Wednesday, April 13th. They issued a “buy” rating and a $15.00 target price for the company. Cowen and Company reissued a “buy” rating on shares of Regulus Therapeutics in a report on Wednesday, June 8th. Wedbush reissued an “outperform” rating and issued a $48.00 target price on shares of Regulus Therapeutics in a report on Friday, April 15th. Finally, BMO Capital Markets started coverage on Regulus Therapeutics in a research note on Monday, April 11th. They set an “outperform” rating and a $16.00 price target for the company. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $10.42.

The company’s market capitalization is $177.87 million. The company has a 50 day moving average price of $4.86 and a 200-day moving average price of $6.21.

Regulus Therapeutics (NASDAQ:RGLS) last issued its earnings results on Monday, May 2nd. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.33) by $0.07. On average, equities analysts expect that Regulus Therapeutics Inc. will post ($1.54) earnings per share for the current year.

A hedge fund recently bought a new stake in Regulus Therapeutics stock. Oxford Asset Management bought a new stake in Regulus Therapeutics Inc. (NASDAQ:RGLS) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 260,798 shares of the biopharmaceutical company’s stock, valued at approximately $2,335,000. Oxford Asset Management owned approximately 0.50% of Regulus Therapeutics as of its most recent SEC filing.

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.